

PERSPECTIVE

Open Access



A perspective on multi-target drug discovery and design for complex diseases

Rona R. Ramsay^{1*}, Marija R. Popovic-Nikolic², Katarina Nikolic², Elisa Uliassi³ and Maria Laura Bolognesi³

Abstract

Diseases of infection, of neurodegeneration (such as Alzheimer's and Parkinson's diseases), and of malignancy (cancers) have complex and varied causative factors. Modern drug discovery has the power to identify potential modulators for multiple targets from millions of compounds. Computational approaches allow the determination of the association of each compound with its target before chemical synthesis and biological testing is done. These approaches depend on the prior identification of clinically and biologically validated targets. This Perspective will focus on the molecular and computational approaches that underpin drug design by medicinal chemists to promote understanding and collaboration with clinical scientists.

Keywords: Multi-target drugs, Neurodegeneration, Cancer, Cheminformatics, Virtual screening, Biological assays

Introduction

Drug discovery in the 21st century has the disadvantage that it is very difficult to get new compounds into the clinic. The diseases where cures or at least treatments are sought are complex ones involving many potential defects in the structure, function, or regulation of the cells involved. Major targets that will be considered here are Alzheimer's (AD) and Parkinson's (PD) diseases of neurodegeneration, and cancer. Despite the complexity of causative factors that can lead to these disease states, the tools of modern drug discovery have the power to cover millions of compounds or fragments and determine their potential association with a target before specific chemical synthesis and biological testing is done. This perspective will focus on the molecular and computational approaches that underpin drug design by medicinal chemists. These approaches require the prior identification of clinically and biologically validated targets, and subsequent experimental testing both in vitro and in vivo. The success of drug design for complex diseases depends on an interdisciplinary and collaborative approach, and

on scientists and clinicians who are willing to communicate and work together throughout the process.

Designing multi-target drugs for complex diseases

The transition from the single-target to the multi-target concept for drug design

Traditionally drugs have been designed with the aim of targeting a single biological entity, usually a protein (the so-called "on-target"), with high selectivity to avoid any unwanted effects arising from mis-targeting other biological targets ("off-targets"). On this basis, the concept of drugs interacting with multiple targets has long been flagged as undesirable, as it was inherently associated with adverse side effects. However, the complexity of the current incurable pathologies has clearly demonstrated that such single-target drugs are inadequate to achieve a therapeutic effect [1, 2]. In parallel, we have learned that molecules hitting more than one target may possess in principle a safer profile compared to single-targeted ones [1, 2].

Building on such accumulating evidence, the concept of multi-target drugs has made rapid and spectacular progress from being an emerging paradigm when first enunciated at the beginning of 2000 [3–5], to one of the hottest topics in drug discovery in 2017. Indeed, in the years, these concepts have triggered the interest of the

*Correspondence: rrr@st-andrews.ac.uk

¹ Biomedical Sciences Research Complex, University of St Andrews, North Haugh, St Andrews KY16 9ST, UK

Full list of author information is available at the end of the article

drug discovery community both in academia and pharmaceutical companies to such a point that a plethora of multi-target drugs are already available on the market.

The analysis of FDA-approved new molecular entities (NMEs) from 2015 to 2017

As a clear proof of such translational success of multi-target drugs into the clinic, we have performed an analysis of the US Food and Drug Administration (FDA)-approved new molecular entities (NMEs) from 2015 to 2017 (status September 2017), following a similar analysis (from 2000 to 2015) made by Lin et al. [6]. The 101 new NMEs on FDA.gov approved over this triennium were classified into NME categories (small molecules, biologics, therapeutic combinations and diagnostics). By using the DrugBank database, which compiles information on approved drugs, together with their target(s) and mechanism(s) of action (MoA), the small molecules have been further analyzed and subdivided into single-target and multi-target drugs. As depicted in Fig. 1, biotech drugs (proteins, peptides and monoclonal antibodies) represent 31% of the novel NMEs, nearly approaching the number of single-target drugs (34%). This clearly reflects the recent increased pharma interest in discovery of biologics [7], which build on the premise of a personalized treatment [8].

Notwithstanding the increase of approved biologics in recent years, small molecules, both single-targeted and multi-targeted ones, continue to contribute. Although the number of single-target small molecules (34%) is still greater than that of multi-target drugs (21%), the latter keeps increasing compared to previous years (16%) [6, 9]. However, if we broaden our view and reason in terms of general polypharmacology, we can add together the 21% of multi-target drugs and the newly approved therapeutic combinations (10%). In this way, the total percentage (31%) approaches that of single-target drugs (34%). This unequivocally supports the attractiveness of polypharmacological strategies, especially in certain therapeutic areas, such as anti-infective, nervous system, and anti-neoplastic agents (Fig. 2).

Examples of multi-target drugs for complex diseases

With regards to anti-infectives, daclatasvir is one of the last approved (2015) non-interferon based agents against hepatitis C virus (HCV), developed to selectively target one of the key viral proteins involved in the HCV replication, i.e. nonstructural 5A (NS5A) phosphoprotein [10]. Despite the high effectiveness, several combination therapies have been approved since January 2016 because drug-resistance is an already established phenomenon [10]. These combinations were all conceived based on the prototypical polypharmacology hypothesis that targeting

FDA-approved agents 2015-2017 (status September 2017)




Fig. 1 Distribution of the new molecular entities (NMEs) approved from 2015 to 2017 (status September 2017), organized according to the different classes of NMEs

two different nodes of HCV replication may exhibit superior antiviral activity compared to single drugs and reduced resistance [11]. These combinations include: (i) elbasvir, a NS5A inhibitor, combined with grazoprevir, a NS3/4A protease inhibitor, (ii) the combination of sofosbuvir, a nucleotide analogue NS5B polymerase inhibitor, and velpatasvir, a NS5A inhibitor, and (iii) the fixed-dose combination of glecaprevir, an NS3/4A protease inhibitor, and pibrentasvir, an NS5A inhibitor [11].

Nervous system application of polypharmacology has led to approval of four multi-target drugs. Recently, an increased number of multi-target drugs have been developed to treat schizophrenia and major depressive disorders [12–14]. The main strategy for treatment of schizophrenia is based on antagonizing dopamine D₂, serotonin 5-HT_{2A} and α 1-adrenergic receptors [15]. Incorporating effects at these broad targets has the objective of either improving antipsychotic efficacy or mitigating adverse effects. With these concepts in mind, starting from the arylpiperazine substructure as suitable scaffold for achieving a fine balancing of D₂, 5-HT_{1A} and 5-HT_{2A} receptors activities, the prototype of the third-generation of antipsychotics, aripiprazole, launched into the market in 2015, was the first designed serotonin-dopamine activity modulator (SDAM). However, it also displayed unwanted side effects, probably arising from a sustained interaction with post-synaptic D₂ receptors. Thus, brexpiprazole was licensed on October 2015 as a novel D₂ and 5-HT_{1A} partial agonist, with less intrinsic activity at D₂ receptors and more balanced activities at 5-HT_{2A}, 5-HT_{1A}, and α _{1B} receptor subtypes than aripiprazole [15].




Fig. 2 The 21 multi-target drugs and 10 therapeutic combinations approved in 2015–2017 organized according to their Anatomical Therapeutic Chemical (ATC) Classification System

Another excellent example is cariprazine, approved by the FDA in September 2015 for the treatment of schizophrenia and bipolar disorders. Similarly to the above mentioned SDAM, cariprazine shares the arylpiperazine substructure linked to an alkyl-*N,N'*-dimethyl urea, which determines a profile of partial agonism at D_2 and D_3 receptors [16]. This mechanism is innovative because many other antipsychotics are only D_2 and 5-HT_{2A} partial agonists (see above).

Concerning neurodegenerative disorders, the polypharmacological approach looks particularly promising, given the complexity and multifactorial nature of such diseases and their unknown etiopathogenesis [17, 18]. For example, rasagiline, approved in 2006 for neurodegenerative diseases, displayed a multi-target profile. The first new chemical entity approved for neurodegeneration in over a decade is a multi-target drug called safinamide. Safinamide was originally developed as anticonvulsant agent [19] and approved in March 2017 as an adjunctive treatment for PD thanks to its particular multi-target profile. It combines dopaminergic effects, including selective and reversible MAO-B and dopamine reuptake inhibition, which are largely responsible for its effects on motor symptoms, along with non-dopaminergic properties, i.e. blockade of voltage-dependent Na^+ and Ca^{2+} channels and consequent inhibition of glutamate release that is thought to confer neurorescue and neuroprotectant effects [20].

Apart from schizophrenia and neurodegeneration, another key disease that would benefit from polypharmacological strategies is cancer, where several aberrant proteins and pathways concur to initiate tumor

growth and to facilitate its progression. Similarly to the above mentioned diseases, redundancies and complexities of biological pathways often lead to compensation and resistance to targeted therapies [21–23]. Among the different classes, multi-kinase inhibitors emerged as the most exploited anti-cancer polypharmacological approach, followed by pan-inhibitors of histone deacetylases (HDACs). Lenvatinib in the first group is a reversible multi-tyrosine kinase receptors inhibitor that modulates the activities of vascular endothelial growth factor receptors (VEGFR) 1–3, fibroblast growth factor receptors (FGFR) 1–3, RET, mast/stem cell growth factor receptor kit (SCFR), and platelet-derived growth factor receptor (PDGFR) beta, all implicated in pathogenic angiogenesis, tumor growth, and cancer progression [24]. Given the broad activity profile, it was approved for the treatment of radioiodine-refractory thyroid cancers. Neratinib is another recently approved multi-tyrosine kinase inhibitor with an irreversible mechanism of action, which exhibits antitumor activity by targeting epidermal growth factor receptor (EGFR), and human epidermal growth factor receptor 2 (HER2), both highly expressed in several carcinomas. Taking advantage of the high sequence identity shared by EGFR and HER-2 (82%) in the ATP domain, the design of such dual-inhibitor bearing a Michael acceptor warhead was undertaken. Computational studies guided the optimization of this molecule so that its warhead is positioned suitably to interact with Cys 773 of EGFR and the analogous Cys 805 of HER-2 [25].

Another well-explored class of multi-kinase inhibitors is represented by dual inhibitors of cyclin-dependent

kinase (CDK) 4 and 6. Starting from the pyrido[2,3-d]pyrimidin-7-one scaffold as template for the inhibition of a broad cross-section of kinases, including pan-CDKs inhibitors which have been discontinued due to the associated toxicity, through a combination of chemical screening and optimization, it was found that the modification at the C2-position provides inhibitors with exquisite selectivity for CDK 4/6. Among them, palbociclib, abemaciclib and ribociclib were approved by FDA as breast cancer therapy in this time frame [26].

Midostaurin, a semi-synthetic derivative of the pan-kinase inhibitor staurosporine, is a well-known multi-kinases inhibitor, approved on April 2017 for the treatment of those adult patients with newly diagnosed acute myeloid leukemia that have a specific variant of the FLT3 gene. It was shown to inhibit the activity of protein kinase C alpha (PKC alpha), VEGFR2, KIT, PDGFR and WT and/or mutant FLT3 tyrosine kinases [27].

Regarding the hot topic of epigenetic polypharmacology [28], panobinostat is a cinnamic hydroxamate-based histone deacetylase inhibitor (pan-HDAC inhibitor) approved on February 2015 by the FDA for the treatment of multiple myeloma in combination with bortezomib (a proteasome inhibitor) and dexamethasone. Nonselective inhibition of both classes (I and II) of HDAC enzymes resulted in increased acetylation of histone proteins, leading to cell cycle arrest and/or apoptosis of cancer cells. However, it is interesting to note that its broad activity profile against HDACs, which depends on zinc chelation for activity, lacks therapeutic efficacy as monotherapy in patients with multiple myeloma, whereas synergistic activity has been demonstrated when used in combination with other drugs targeting different hubs of the tumor network [29]. This lends support to the concept that the network disruption approach is highly valuable in anti-cancer drug discovery.

Current challenges of rational design of multi-target drugs

From these data, we can conclude that the time is ripe to extend applicability of multi-target drugs and polypharmacology across different therapeutic areas. However, how to develop them in a rational way is still a big challenge, both in terms of target selection and small molecule discovery [30–32]. Regarding the first issue, although there is a variety of valuable online resources [33–35], it is still a challenge to choose the right combination of targets for the disease of interest in both multi-target drugs and therapeutic combinations. It requires good understanding of target-disease associations, pathway-target-drug-disease relationships and adverse events profiling [36]. Furthermore, the selection should be based on whether or not modulating the selected targets could

lead to additive or synergistic effects [37]. Particularly, additive effects can be obtained when the targets belong to the same pathway, whereas synergism can be achieved only if the selected targets are located on functionally complementary pathways. This means that in both cases the effect is attained at lower doses, and consequently a better safety profile can be expected with respect to single-target drugs [37].

With regards to the second issue, although early drugs were discovered serendipitously, multi-target compounds are now rationally designed, typically by combining two distinct frameworks into a single chemical entity [38–40], starting from compounds with the desired activity towards the targets of interest. Thus, multi-target compounds routinely result from the integration of pharmacophores of selective molecules, either already known drugs or drug candidates (Fig. 3). Intuitively, pharmacophores featuring similar scaffolds, usually ring systems, can be fused or merged depending on the overlapping degree between the starting frameworks. Alternatively, if pharmacophores present different structural elements required for the interaction with each target, they can be conjugated with cleavable or non-cleavable linkers, although this strategy often leads to molecules with poor drug-likeness properties [41]. In all cases, the generation of multi-target compounds is typically driven by the nature of the targets, the availability of starting frameworks and the chemical tractability. Beyond that, the essential requirement of the multi-target compounds is that each framework retains the ability to interact with its specific target [32]. This undoubtedly challenging task involves considering structure–activity relationships that govern the interaction of the starting molecules with their specific targets, and becomes most challenging when these targets are only slightly related or unrelated (i.e. when they belong to different protein families) [32].

Furthermore, establishing the same degree of modulation for each target (i.e. balancing the activities towards the targets) and “designing out” unwanted interactions to any undesired target (off-target) are critical factors to be addressed. The latter aspect is of particular importance when designing multi-target compounds directed to targets belonging to the same family (e.g., multi-kinases inhibitors), but also in the case of shared functional domains and/or binding sites across target families [32]. Clearly, the rational design of multi-target compounds is far from being an easy task, dealing with the crucial issues of selecting the right target combination, achieving a balanced activity towards them, and excluding activity at the undesired target(s), while at the same time retaining drug-like properties.




Fig. 3 Rational design of multi-target compounds

The tools to identify hits/leads

Computational approach to ligand discovery and back validation of hits by docking

Rational drug design is extensively applied in the search for novel agents as an efficient tool for hit identification, validation, optimization, and evaluation. Computational approaches such as cheminformatics and virtual screening, pharmacophore development, molecular docking and molecular dynamics are mainly used to identify new agents, define molecular determinants for enhanced activities, design and evaluate more efficient drugs with improved safety [42].

The structure-based *in silico* methods use structures of ligand-target complexes to identify the structural origins of activity and selectivity of related ligands. Ligand-based computational methods are able to determine essential structural features for a set of bioactive ligands and identify the structure of potential lead molecules [43]. Novel *in silico* methods that combine ligand and structure activity relationship methods provide the most comprehensive information about drug-target interaction and significantly increase the success rate of the rational drug design [44–46]. Different computational approaches for ligand discovery have been developed helping to reduce late stage attrition and to limit the number of expensive and time consuming experiments required to synthesize the active novel hits with optimized pharmacodynamic

and pharmacokinetic properties [47]. The importance of wide application of computational methods in drug discovery processes has been extensively reviewed [48, 49].

A commonly used cheminformatics methodology for lead identification is similarity-based. Molecular similarity between chemical structures from *in silico* libraries and molecules already known to possess activity against protein target is used to predict bioactivity. Unlike the simplest approach for single-targets, this method can be modified for application on multi-target problems with some missing data. In that case, the researchers do not base their search on single known active compound, but rather on families of compounds [50]. Another modification that can be applied to multi-target problems is a quantitative method of estimating the probability that a certain molecule is associated with the particular bioactivity-scaffold combination defining one specific refined family [49]. Subsequently, more complex methods can help to make comparable predictions of not only a query activity but also molecules with off-target and promiscuous interactions. This approach was successfully implemented for the identification of performance-enhancing molecules that should be prohibited in sports [50], and for predicting multi-target bioactivities of potential polypharmacological compounds for treatment of neurological diseases [51]. Cheminformatics-based target identification has been applied for identification of

multi-target ligands intended to interact with MAO-A and MAO-B; acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE); or with histamine *N*-methyltransferase (HMT) and histamine H₃-receptor (H₃R) [51].

Quantitative structure–activity relationship (QSAR)

Quantitative structure–activity relationship (QSAR) modelling, widely used for development of the biological and physical properties of new compounds, is a crucial initial step in lead optimization to correlate molecular structure with biological and pharmaceutical activities

(Fig. 4). This approach selects molecular descriptors that are representative of the molecular features responsible for the relevant molecular activity. The usefulness of these descriptors in QSAR studies has been extensively demonstrated, and they have also been used as a measure of structural similarity or diversity [45, 47]. The 2D-QSAR methods require lower calculation times which allow them to be used mostly as preliminary filters to reduce the number of compounds that require further screening in later stages of drug development. The 3D-QSAR approach is used to construct a tridimensional structure of the pharmacophore and to define the




Fig. 4 Schematic representation of the QSAR workflow

functional links between the 3D-molecular determinants and the activity [47]. The important advantage of QSAR modeling is an understanding of the effect of chemical structure on activity. When a large amount of experimental data is available, QSAR makes possible the selection of the best candidates for the synthesis of novel compounds. Interpolation can be applied, but it must be taken into account that extrapolation should not be extended outside the scope of the data set. The results obtained in this way can be used to understand the productive interactions between functional groups in the molecules and those in their target. On the other hand, QSAR modeling can have several disadvantages. False correlations can occur if the biological data used include experimental errors. Sometimes QSAR results cannot select the most active compounds with a suitable degree of confidence if the underlying experiments do not include a complete sense of experimental design [41, 42, 47]. Successful examples of the 3D-QSAR approach and related chemoinformatic methods application are described in comprehensive overview about the development of tacrine- and donepezil-like multitarget compounds for the treatment of AD [44, 52].

Virtual screening (VS)

Virtual screening (VS) is a reliable, inexpensive method for identifying leads by providing the screening of whole libraries of small molecules in order to get practically achievable number of compounds with the structures of the highest probability of binding to a drug target [53]. VS, a computational method with an essential role in drug discovery and an alternative to experimental high throughput screening, can be classified into two techniques: ligand-based virtual screening (LB-VS) and structure-based virtual screening (SB-VS). LB-VS approaches are based on analysis of a miscellaneous set of ligands in order to define pharmacophore for further score and are usually applied when no structural information about the target protein is available. SB-VS can be employed when the three-dimensional structure of target protein is known from X-ray crystallography or nuclear magnetic resonance (NMR) spectroscopy. This technique involves molecular docking of each ligand into the binding site, followed by ranking of the compounds based on their likely affinity for the biomolecular target. The techniques of VS often require construction of an *in silico* library of compounds which could readily be synthesized once they have been selected from a virtual screen [54].

Examples of application of SB-VS in lead discovery have been reviewed by Sliwoski et al. [53]. One of the most successful is SB-VS of 0.7 million compounds from the database rCat [55] with Hsp90, an important therapeutic target for oncology, which allowed identification

of lead compounds and their development to potent inhibitors of Hsp90. In another example, a homology model of M1 acetylcholine receptor (mAChR) based on crystal structure of bovine rhodopsin, served for VS and led to development of a series of novel 1-(*N*-substituted piperidin-4-yl) benzimidazolones [53].

In addition to independent application, the combination of the structure- and ligand-based VS strategies can be also implemented in lead identification studies where all available chemical and biological information are taken into account. Lepailleur and co-workers applied pharmacophore-based virtual screening in combination with similarity based clustering method and molecular docking to identify dual H₃R antagonist/5-HT₄R agonists [56]. Binding experiments confirmed that benzo[*h*]-[1,6] naphthyridine ligands selected by this VS approach exert high affinity for both H₃ and 5-HT₄ receptors. Recently, Bottegoni et al. [57] carried out a VS protocol to identify fragments that display considerable activity at both β -secretase1 (BACE-1) and glycogen synthase kinase 3 β (GSK-3 β), two structurally unrelated enzymes associated with the onset of AD.

Perhaps one of the best examples that describe the application of computer approaches in drug development is ligand discovery for the treatment of AD. A virtual ligand screen was applied for lead optimization of two donepezil hybrid compounds that inhibit MAO-A, MAO-B, AChE, and BuChE. The experimental results confirmed the quality of the 3D-pharmacophores showing that the most potent against all four enzymes were the compounds selected by the models from previous 3D-QSAR analyses as the best candidates [58, 59]. The synthesis and pharmacological evaluation of new donepezil-indolyl hybrids [58, 59] and donepezil-pyridyl [60] as multifunctional drugs for the potential treatment of AD, using the multipotent reference compound ASS234 have also been reported by the same group. Potential for development of multiple ligands for dopamine receptors involved in numerous neurological disorders was comprehensively reported by Butini et al. [61]. Rational design and a computational approach were used for identification of a new series of 1,2,4-triazol-yl-azabicyclo[3.1.0]hexanes as a D₃ receptor antagonists [62] with high *in vitro* affinity and selectivity at the D₃ receptors. On the basis of the profile of aripiprazole a series of new antipsychotics with affinities at D₃ and D₂ receptors were developed [63], where compound cariprazine has passed clinical evaluation and was approved by the FDA for schizophrenia and bipolar disorders in 2015.

The most important advantages of VS compared to laboratory experiments or high-throughput screening (HTS) are capacity for testing large *in silico* libraries of compounds, price, speed, and safety. The VS

analysis can be applied to reduce the initial number of compounds before using HTS methods. VS approaches allow investigation of compounds that have not yet been synthesized or purchased. Some disadvantages of VS arise from the fact that VS cannot completely replace the experimental HTS which can test the activity of hundreds to thousands of compounds against the target and which provides essential results for further drug discovery.

Molecular docking

To confirm all predictions and perform back validation of hits, molecular docking studies can be conducted before compound synthesis. Molecular docking is a computational technique that can be used to model the interaction between a small molecule and a target protein at the atomic level, subsequently providing the prediction of which conformation best fits the protein binding site and an estimate of the stability of the ligand–protein complexes [64]. The most often used docking software packages are CDOCKER [65], GOLD [66] and AutoDock [67]. Knowing the location of the binding site beforehand allows a small part of the protein to be studied and significantly increases the docking efficiency. Generally, objective functions are calculated and used to analyse possible conformations of ligands, to search for the most stable binding modes of the ligands with the target, and to optimize the geometry of docked ligand–target complexes. It would be too expensive to generate all the possible conformations, so various sampling algorithms are developed to reproduce the binding mode and to provide scoring functions to rank all generated conformations. Programs based on different algorithms have made docking an increasingly important tool in pharmaceutical research.

The main advantages of using molecular docking methodology are to analyse the binding modes of the ligand with the target, compare binding energies of various ligands, and estimate stability of docked ligand–target complexes. The objective and scoring functions used in docking reflect the fact that binding of a ligand to its target is partly based on their chemical complementarities and physicochemical interactions, and partly on shape complementarities, which may well be conformation-dependent. Flexibility of the target biomolecule can be modelled either by performing virtual docking to set of rigid protein conformations or by examining dynamic ligand–target complexes. A combination of molecular docking and molecular dynamic studies can therefore be used to select the key interactions between the ligands and the targets that must be retained in new molecules.

Examples of successful implementation of the docking simulations can be illustrated by the studies of novel multi-target compounds for neurodegenerative diseases (Table 1). Molecular modeling analysis and docking simulations, using the program Autodock Vina and the Protein Data Bank crystal structures of four enzymes (AChE/BuChE/MAO-A/MAO-B), conducted on a series of experimentally synthesized donepezil-indolyl hybrids [59] and donepezil-pyridyl hybrids [60] revealed that compounds DIH15 [59] and DPH14 [60] expressed the best observed drug-like characteristics and might be considered as a promising compounds for further development for the treatment of AD. Moreover, a series of docking simulations identified the most promising donepezil hybrid [68] as an interesting lead compound for the design of novel MTDL for AD therapy, ready for experimental validation. The subsequent experimental validation of predicted hits is the only indicator of actual reliability of implemented computational approach and

Table 1 The examples of successful docking studies used in ligand discovery for the treatment of AD

Novel ligand	Target	PDB	Ligand-receptor interactions	Refs.
Donepezil-indolyl hybrid (DIH15)	AChE	1C2B	Tyr124, Tyr341, Phe338, Trp286, Tyr72	[59]
	BuChE	2PM8	Ser198, His438, His438, Trp82, Trp231	
	hMAO-A	2Z5X	Glu215, Val93, Leu97, Ala111, Tyr407, Tyr444, FAD, Cys323	
	hMAO-B	2V5Z	FAD, Leu 88, Pro102, Ile316	
Donepezil-pyridyl hybrid (DPH14)	AChE	1C2B	Trp286, Tyr124, Trp86, Tyr124, Tyr337, Tyr341, Tyr72, Tyr124, Asp74	[60]
	BuChE	2PM8	Trp82, Ser198, Leu286, His438, Tyr332	
	hMAO-A	2Z5X	Tyr407, Tyr444, Gln215, Ser209, Val93, Leu97, Ala111	
	hMAO-B	2V5Z	Tyr398, Tyr435, Gln206, Cys172, Pro102, Thr201, Thr314, Ile316	
Donepezyl hybrid (compound 5)	AChE	1EVE, 2CKM, 1Q83	Trp279, Trp84, Tyr334, Asp72, Tyr70, Phe330	[68]
	BuChE	2PM8	Trp79, Phe330, Tyr70, Phe290, Trp279	
	hMAO-A	2Z5X	Phe208, Ile325, Leu97, Leu337, Val210, Cys323, Arg109, Gly110	
	hMAO-B	2BYB	Ile199, Ile316, Tyr326, Arg100, Gly101, Glu84, Leu88	

represents the critical step which should be a standard component that follows any ligand discovery process [45].

Computational approaches to druggability

Multi-potent inhibitors of cholinesterases and monoamine oxidases were proposed as novel agents for therapy of AD and PD [51, 59, 68–71]. Ladostigil and rasagiline, drugs acting as inhibitors of monoamine oxidase, are propargylamine derivatives able to retard neurodegeneration and decrease deposition of A β -containing plaques. Therefore, these agents were selected for clinical trials as novel drug candidates in therapy of AD. The completed phase II clinical trials for ladostigil (NCT01354691) and rasagiline (NCT00104273) were an important proof of concept for MTDL as novel drugs in therapy of AD.

The effectiveness of CNS drugs depends on drug penetration through the blood–brain barrier (BBB) between the blood capillaries and brain tissue, the extent of distribution of the drug in the brain, and the drug activities on the targets. These multiple factors increase the complexity of CNS drug discovery [72]. The main parameter of interest is the unbound brain concentration ($C_{u,b}$) of the drug. The $C_{u,b}$ can be directly related to the drug concentration at the target site and thus to in vivo drug efficacy. Receptor occupancy is also very important experimental descriptor for evaluating target engagement by the examined drug. Total brain concentration (C_b) is only used as measure of the nonspecific binding of the drug to brain [73, 74]. The development of quantitative structure–exposure relationships between molecular parameters of drugs and experimental parameters of their brain exposure is now a valuable tool for predicting CNS drug efficacy [74, 75].

The most important physicochemical factors for CNS drug penetration in brain and for efficacy are optimal lipophilicity, hydrogen bonding, aqueous solubility, pK_a , and molecular weight of agents. Moderate lipophilicity of CNS drugs at physiological pH [cLogP: 2–5, cLogD (pH 7.4): 2–5] facilitate transport through BBB [76], while higher lipophilicity increase plasma protein binding, decrease solubility in plasma, and rise metabolic and toxicity risks of the agents [77].

Hydrogen bonding parameters, such as hydrogen bond donor (HBD) and hydrogen bond acceptor (HBA) counts, are dominant descriptors for unbound brain concentrations ($C_{u,b}$) of agents as crucial measure of in vivo CNS drug efficacy [78]. Reducing the HBD and HBA counts (HBD < 3; HBA < 7) [72, 76] of a drug is a key step applied in optimizing drug brain exposure [79]. Moderate lipophilicity (cLogP < 4) together with considerable topological polar surface area (TPSA 40–80 Å²) are defined as optimal combination of parameters for increased

unbound brain concentrations of CNS drugs [80]. Aqueous solubility can also be examined in combination with the above molecular properties. Most CNS drugs showing aqueous solubility of more than 100 μ M have low safety risk [81].

Current CNS drug discovery applies computational approaches to propose structural modifications of investigated compounds for better brain penetration and in vivo drug efficacy. Design of CNS drug candidates with optimal balance between physicochemical properties for efficient brain exposure is now the big challenge in CNS drug discovery [82–84]. Thus, future CNS drug design will include developments of predictive computational methods and exploring of CNS property space for more efficient penetration in brain and enhanced efficacy [74, 75].

Biological validation of leads

The biological side of drug discovery is intimately integrated to the process of high-throughput compound assessment. Computational searches are underpinned by the prior identification of targets for specific medical conditions and by the crystal structures or at least a detailed pharmacophore derived from in vitro structure–function studies. The large numbers of hits from computation searches then require high throughput assessment using chemical libraries and assays for the specific targets. This section will focus on the types of assays used in small-scale academic laboratories, but adaptation to high throughput and multiplexed methods are now also essential for translational drug discovery.

Most disease-modifying targets can be divided into the three categories: receptors, enzymes, or macromolecule interactions. For all of these assessing binding is the primary goal. The initial hits from binding (either computationally or experimentally determined) are then further discriminated using more in depth methodologies. The biological information is fed back into the chemical development to optimize the hits to provide lead compounds to explore for toxicity and for efficacy in higher-level systems. It is at the hit-to-lead stage that academic groups both in medicinal chemistry and in biological and medical sciences can make substantial contributions, particularly with the improved biophysical technologies now available [85, 86].

The initial screening of compounds for biological activity should ideally give values that can be compared with other studies. Limitations on materials or time are often restrictive when screening large numbers of compounds. Table 2 compares some parameters that can be obtained for receptors, enzymes, proteins and cells at the simplest level. Measuring effects that result from the association of ligand and its target can be more convenient, and is

Table 2 Increasing complexity of measurements for assessing new compounds in vitro

Target	Parameters	Effects
Receptor (R)	$L + R \xrightleftharpoons[k_{\text{off}}]{k_{\text{on}}} LR \rightarrow \text{conformational change}$	Multiple effects possible: on, off, partial, etc
Enzyme (E)	$\text{Reversible } L + E \xrightleftharpoons[k_{\text{off}}]{k_{\text{on}}} LE$ $\text{Irreversible } L + E \xrightleftharpoons[k_{\text{off}}]{k_{\text{on}}} LE \xrightarrow{k_{\text{inact}}} L - E$	<p>Decreases product, prevents depletion of substrate but can be out-competed by substrate</p> <p>Inactivated enzyme; recovery depends on normal turnover of enzyme (minutes to days)</p>
Protein or DNA (M)	$L + M \xrightleftharpoons[k_{\text{off}}]{k_{\text{on}}} LM$	Ligand and target often at same concentration in vitro. Outcome of binding best measured downstream
Cell target (T)	$L_{\text{out}} \xrightarrow{\text{cell uptake}} L_{\text{in}} \xrightarrow{\text{metabolism?}} \begin{matrix} \text{Organelle uptake} \\ \text{Other binding} \end{matrix} \rightarrow L + T \xrightleftharpoons[k_{\text{off}}]{k_{\text{on}}} LT$	<p>Concentration at target site unknown</p> <p>Major effects often easy to assess (e.g., cell death) but mechanism can be obscure</p>

often more informative, certainly for receptors, the first of the targets to be considered below.

Receptors

In the last 20 years, advances in cloning and purification of membrane-bound proteins and in crystallography and other methods of structural determination have enabled the structural characterisation of large numbers of receptors. The GPCR family has moved on from a few structures and use of derived homology models to a database of structures and experimental parameters, and full sets of expressed receptor subtypes [87–89]. Many small commercial labs now offer screening services for academic researchers. With one GPCR-targeted AD drug in use (memantine, a NMDA receptor agonist), GPCR ligands are also interesting for multi-target compounds. A recent example for AD added a histamine receptor antagonist moiety to cholinesterase and monoamine oxidase inhibition [90]. However, it is the downstream effects and integration of signalling that are important. For a given cell, the challenge of understanding the action of multiple ligands on many GPCRs linked to multiple signaling routes can now be addressed using systems biology approaches to deconvolute the spatiotemporal phenomena of intracellular signal integration [91].

Designing ligands for GPCRs is not a trivial task. Understanding exactly how ligands induce agonism or antagonism involves complex allosteric effects [92]. Progress in this area is currently an exciting area of drug design (for example, [93]) producing more specific ligands for pharmacological use. The flexibility of the GPCR proteins also leads to in vivo complexity. Transient dimerization [94], heterodimers [95], and internalized megamers [96] are now beginning to be explored both to understand the signaling involved in cells and in vivo, and to design selective ligands that promote different aggregation states.

Enzymes

Since almost half of current drugs work on enzymes, evaluation of binding to active sites and the effect on the kinetics of the enzyme remain primary in vitro tools. Evaluation of binding to purified enzymes by surface plasmon resonance (measuring on- and off-rates and affinity constants) is the major high through-put tool but isothermal titration calorimetry (ITC, measuring binding affinity and stoichiometry) is also used. As for receptors, tuning the functional effect of binding is even more important. Ligands that compete with the native substrate are relatively easy to design but effective drugs are usually non-competitive or have a long residence time (slow off-rate) or are irreversible inhibitors of enzyme activity [97–99]. Assessment of the enzyme kinetics usually uses a specific assay detecting the change in the substrate or (better) in the product using absorbance or fluorescent detection. Increased sensitivity for an assay can be devised by designing fluorescence probes or by coupling the assay product to another (excess) enzyme that converts the product into something measurable. The desired output in initial compound screening is an IC_{50} value. This is a simple way of comparing a series of compounds assayed under the same conditions but does not allow comparisons with other series or work using other assays. For enzymes, it is much more informative to measure defined parameters (such as K_D or K_i) that can be compared with computed binding constants, and can be used in modelling complex pathways. It should be noted that the relationship of IC_{50} to K_i from enzyme kinetics depends on the mechanism of inhibition [100].

Cell-based assays

Designing drugs to combat neurodegeneration has always looked to cell survival as an ultimate target because cell death is involved both in PD (specifically in the substantia nigra) and in AD (general neuronal loss). Anti-oxidant

activity, a target of early research, is still seen as desirable in compounds such as rasagiline. Further, the propargyl moiety of L-deprenyl was found to have neuroprotective effects, up-regulating cell survival pathways [101, 102].

Testing effects of chemicals on mitochondrial health requires more sophisticated methods. The primary goal is to protect ATP generation, best measured in intact cells by the respiratory capacity and the response to probes of mitochondrial oxidative phosphorylation. Using neuronal or glial cell cultures, the parameters of ATP turnover, proton leak, and maximum respiration rate can be determined using a dedicated analyzer (Seahorse XF) to measure the oxygen consumption rate (cell respiration) and extracellular acidification rate (an indicator of glycolysis) and how these respond to additions of oligomycin and respiratory inhibitors [103]. Live cell imaging with a chemical probe can be used to determine reactive oxygen species (ROS) production (a sign of damaged mitochondria or inhibited electron transport) and mitochondrial membrane potential. It is particularly valuable for visualizing mitochondrial movement [104] or morphology (MitoRed staining) that is an indicator of mitochondrial health or stress. Other biochemical methods augment the information, such as mRNA or protein levels of proteins involved in mitochondrial movement, biogenesis, fission and fusion (for example, [105, 106]). When the target is inside mitochondria, designing compounds to deliver a drug specifically to mitochondria is possible. Compounds with a shielded positive charge will penetrate the membranes but be accumulated in response to the membrane potential as shown for the neurotoxin MPP⁺. This strategy was exploited in the design of a compound to treat malignant gliomas [107].

The uncertainty for testing in complex systems is larger than for isolated or over-expressed enzymes or receptors, so in practice, IC₅₀ values or the concentrations required to give a fixed endpoint are used for comparisons within a series of compounds. With uptake, compartmentation, non-specific binding, and metabolism to contend with, defined conditions and suitable statistical tests (and sample size) are essential.

Extending cell-based assays to organs or model animals introduces even more complexity, but a study of the toxicity of anti-inflammatory drugs showed reasonable concordance of toxic/non-toxic compounds in isolated mitochondria, rat hepatocytes, and a zebrafish model [108]. Metabolism can vary by species: for example, a novel propargylamine compound with pro-cognitive properties, *N*-(furan-2-ylmethyl)-*N*-methylprop-2-yn-1-amine (FMPA), was stable when incubated with human microsomes but was rapidly metabolized by rat microsomal CYPs [109]. For practical testing of large numbers

of compounds in complex systems, the organ-on-a-chip is on the horizon [105]. It will allow deeper probing of action in a system close to reality but not yet in vivo, thus reducing the need for large numbers of animal experiments, and improving the foundation for the choice of compounds for in vivo studies.

Conclusions

There is ongoing need to find more effective drugs to treat infection where adaptation of the invader resulting in resistance is a problem, to combat cancer where advanced understanding of the mechanisms now requires selective combinations for specific cancers, and to halt progression in AD where only symptomatic therapies are available. Computational methods have enormously increased the rational approach to drug design in recent years, building on the molecular structure determinations of previous decades (a process still ongoing for membrane proteins such as receptors). QSAR methodology has been applied to define molecular determinants for ligand effects on the target, to design novel structures, and to select the best candidates for further studies. Virtual screening approaches have been used to rank the designed compounds with big databases and for lead searches in large in silico libraries of compounds. Based on the molecular docking, dynamic studies explain binding, compare stability of the ligand–protein complexes, and enable determination of interactions important in the binding modes of the ligands.”

In diseases where single-target drugs have failed or show severe limitations, multi-target drugs emerge as more effective therapeutics. Herein, we have outlined current medicinal chemistry approaches that seek the initial tools to better define causative mechanisms and targets to which novel multi-target drugs should be directed. Prediction of the correct targets to combine relies on clinical experience from single-target drugs, an area that should be boosted considerably by quantitative systems pharmacology, a computer-based methodology that combines preclinical neuropharmacology, neurophysiology and existing clinical information, allowing testing of combinations in a virtual human patient [110]. Despite the tremendous therapeutic potential of multi-target drugs, their rational discovery and their development still represent a formidable challenge. In addition, translational barriers remain a problem either for single- or multi-target drugs, as discussed for AD in [111]. However, we foresee that new multi-target molecular entities, well characterized at the chemical, theoretical and biological level, offer a path to progress both in understanding causes of disease and in defining effective small molecule treatments.

Abbreviations

AChE: acetylcholinesterase; AD: Alzheimer's disease; ATC: Anatomical Therapeutic Chemical (Classification System); A β : amyloid β ; BACE-1: β -secretase 1; BBB: blood–brain barrier; BuChE: butyrylcholinesterase; Cb: total brain concentration; Cu,b: unbound brain concentration; CDK: cyclin-dependent kinase; CNS: central nervous system; CYP: cytochrome P450; EGFR: epidermal growth factor receptor; FDA: Food and Drug Administration; FGFR: fibroblast growth factor receptors; FMPA: *N*-(furan-2-ylmethyl)-*N*-methylprop-2-yn-1-amine (a propargylamine inhibitor of MAO); GPCR: G-protein coupled receptor; H3R: histone type 3 receptor; HBA: hydrogen bond acceptor; HBD: hydrogen bond donor; HCV: hepatitis C virus; HDAC: histone deacetylase; HER2: human epidermal growth factor receptor 2; 5-HT: serotonin; 5-HT4R: serotonin receptor type 4; LB-VS: ligand-based virtual screening; mAChR: muscarinic M1 acetylcholine receptor; MAO: monoamine oxidase; MoA: mechanism(s) of action; MTD: multi-target drugs; MTDL: multi-target designed ligand; NME: new molecular entities; NMR: nuclear magnetic resonance (NMR) spectroscopy; PD: Parkinson's diseases; PDGFR: platelet-derived growth factor receptor beta; QSAR: quantitative structure–activity relationship; RET: mast/stem cell growth factor receptor kit (SCFR); ROS: reactive oxygen species; SB-VS: structure-based virtual screening; SDAM: serotonin-dopamine activity modulator; VEGFR: vascular endothelial growth factor receptors; VS: virtual screening.

Authors' contributions

EU and MLB analyzed the new molecular entities approved from 2015 to 2017. All authors wrote sections of the manuscript. RRR compiled the sections; EU compiled the references. All authors read and approved the final manuscript.

Author details

¹ Biomedical Sciences Research Complex, University of St Andrews, North Haugh, St Andrews KY16 9ST, UK. ² Department of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Belgrade, Vojvode Stepe 450, 11000 Belgrade, Serbia. ³ Department of Pharmacy and Biotechnology, Alma Mater Studiorum-Bologna University, Via Belmeloro 6, 40126 Bologna, Italy.

Acknowledgements

The collaboration amongst the authors is facilitated by meetings supported by EU COST Action CM15135, "Multi-target paradigm for innovative ligand identification in the drug discovery process" (MuTaLig, <http://www.mutalig.eu/>). Support by COST Action CM1406 is also acknowledged.

Competing interests

The authors declare that they have no competing interests.

Availability of data and materials

Not applicable.

Consent for publication

Not applicable.

Ethics approval and consent to participate

Not applicable.

Funding

KN and MPN acknowledge national project number 172033 supported by the Ministry of Education, Science and Technological Development of the Republic of Serbia.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Received: 1 November 2017 Accepted: 30 December 2017

Published online: 17 January 2018

References

- Bolognesi ML (2013) Polypharmacology in a single drug: multitarget drugs. *Curr Med Chem* 20(13):1639–1645
- Bolognesi ML, Cavalli A (2016) Multitarget drug discovery and polypharmacology. *ChemMedChem* 11(12):1190–1192
- Morphy R, Kay C, Rankovic Z (2004) From magic bullets to designed multiple ligands. *Drug Discov Today* 9(15):641–651
- Youdim MBH, Buccafusco JJ (2005) Multi-functional drugs for various CNS targets in the treatment of neurodegenerative disorders. *Trends Pharm Sci* 26(1):27–35
- Roth BL, Sheffler DJ, Kroeze WK (2004) Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia. *Nat Rev Drug Discov* 3(4):353–359
- Lin HH, Zhang LL, Yan R, Lu JJ, Hu YJ (2017) Network analysis of drug-target interactions: a study on FDA-approved new molecular entities between 2000 to 2015. *Sci Rep* 7:12230
- Griesenauer RH, Kinch MS (2017) 2016 in review: FDA approvals of new molecular entities. *Drug Discov Today* 22(11):1593–1597
- Schellekens H, Aldosari M, Talsma H, Mastrobattista E (2017) Making individualized drugs a reality. *Nat Biotechnol* 35(6):507–513
- Lu JJ, Pan W, Hu YJ, Wang YT (2012) Multi-target drugs: the trend of drug research and development. *PLoS ONE* 7(6):e40262
- Gao M, Nettles RE, Belema M, Snyder LB, Nguyen VN, Fridell RA et al (2010) Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect. *Nature* 465(7294):96–100
- Bartenschlager R, Lohmann V, Penin F (2013) The molecular and structural basis of advanced antiviral therapy for hepatitis C virus infection. *Nat Rev Microbiol* 11(7):482–496
- Bannwart LM, Carter DS, Cai HY, Choy JC, Greenhouse R, Jaime-Figueroa S et al (2008) Novel 3,3-disubstituted pyrrolidines as selective triple serotonin/norepinephrine/dopamine reuptake inhibitors. *Bioorg Med Chem Lett* 18(23):6062–6066
- Seeger TF, Seymour PA, Schmidt AW, Zorn SH, Schulz DW, Lebel LA et al (1995) Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity. *J Pharmacol Exp Ther* 275(1):101–113
- Felice D, Gardier AM, Sanchez C, David DJ (2017) Innovative solutions to the development of novel antidepressants. In: Carvalho AF, Reus GZ, de Quevedo JL (eds) *Frontiers in drug discovery: the search for antidepressants - an integrative view of drug discovery*, vol 2, pp 1–40. <https://doi.org/10.2174/9781681084732117020004>
- Maeda K, Sugino H, Akazawa H, Amada N, Shimada J, Futamura T et al (2014) Brexpiprazole I: in vitro and in vivo characterization of a novel serotonin-dopamine activity modulator. *J Pharmacol Exp Ther* 350(3):589–604
- Frankel JS, Schwartz TL (2017) Brexpiprazole and cariprazine: distinguishing two new atypical antipsychotics from the original dopamine stabilizer aripiprazole. *Ther Adv Psychopharm* 7(1):29–41
- Cavalli A, Bolognesi ML, Minarini A, Rosini M, Tumiatti V, Recanatini M et al (2008) Multi-target-directed ligands to combat neurodegenerative diseases. *J Med Chem* 51(3):347–372
- Viaña E, Sola I, Di Pietro O, Muñoz-Torrero D (2013) Human disease and drug pharmacology, complex as real life. *Curr Med Chem* 20(13):1623–1634
- Pearello P, Bonsignori A, Dostert P, Heidempergher F, Pinciroli V, Colombo M et al (1998) Synthesis and anticonvulsant activity of a new class of 2-[(ary-alkyl)amino]alkanamide derivatives. *J Med Chem* 41(4):579–590
- Marzo A, Dal Bo L, Monti NC, Crivelli F, Ismaili S, Caccia C et al (2004) Pharmacokinetics and pharmacodynamics of safinamide, a neuroprotectant with antiparkinsonian and anticonvulsant activity. *Pharmacol Res* 50(1):77–85
- Peters JU (2013) Polypharmacology—foe or friend? *J Med Chem* 56(22):8955–8971
- Li YH, Wang PP, Li XX, Yu CY, Yang H, Zhou J et al (2016) The human kinome targeted by FDA approved multi-target drugs and combination products: a comparative study from the drug-target interaction network perspective. *PLoS ONE* 11(11):e0165737
- Santos R, Ursu O, Gaulton A, Bento AP, Donadi RS, Bologa CG et al (2017) A comprehensive map of molecular drug targets. *Nat Rev Drug Discov* 16(1):19–34
- Okamoto K, Kodama K, Takase K, Sugi NH, Yamamoto Y, Iwata M et al (2013) Antitumor activities of the targeted multi-tyrosine kinase inhibitor lenvatinib (E7080) against RET gene fusion-driven tumor models. *Cancer Lett* 340(1):97–103

25. Tsou HR, Overbeek-Klumpers EG, Hallett WA, Reich MF, Floyd MB, Johnson BD et al (2005) Optimization of 6,7-disubstituted-4-(arylamino) quinoline-3-carbonitriles as orally active, irreversible inhibitors of human epidermal growth factor receptor-2 kinase activity. *J Med Chem* 48(4):1107–1131
26. Asghar U, Witkiewicz AK, Turner NC, Knudsen ES (2015) The history and future of targeting cyclin-dependent kinases in cancer therapy. *Nat Rev Drug Discov* 14(2):130–146
27. Levis M (2017) Midostaurin approved for FLT3-mutated AML. *Blood* 129(26):3403–3406
28. Ganesan A (2016) Multitarget drugs: an epigenetic epiphany. *ChemMedChem* 11(12):1227–1241
29. Moore D (2016) Panobinostat (Farydak): a novel option for the treatment of relapsed or relapsed and refractory multiple myeloma. *Pharm Ther* 41(5):296–300
30. Morphy JR, Harris CJ (2012) Designing multi-target drugs. The Royal Society of Chemistry, Cambridge, pp P001–P365
31. Peters JU (2012) Polypharmacology in drug discovery. Wiley, Hoboken
32. Decker M (2017) Design of hybrid molecules for drug development. Elsevier, Amsterdam
33. Multiple target ligand database. <http://www.mtdcadd.com>. Accessed 19 Oct 2017
34. DrugBank. <https://www.drugbank.ca>. Accessed 19 Oct 2017
35. Therapeutic target database. <http://bidd.nus.edu.sg/group/ttd/ttd.asp>. Accessed 19 Oct 2017
36. Hopkins AL (2008) Network pharmacology: the next paradigm in drug discovery. *Nat Chem Biol* 4(11):682–690
37. Bottegoni G, Favia AD, Recanatini M, Cavalli A (2012) The role of fragment-based and computational methods in polypharmacology. *Drug Discov Today* 17(1–2):23–34
38. Morphy R, Rankovic Z (2010) Design of multitarget ligands. In: Rankovic Z, Morphy R (eds) Lead generation approaches in drug discovery. Wiley, Hoboken, pp 141–164
39. Morphy R, Rankovic Z (2009) Designing multiple ligands—medicinal chemistry strategies and challenges. *Curr Pharm Des* 15(6):587–600
40. Morphy R, Rankovic Z (2005) Designed multiple ligands. An emerging drug discovery paradigm. *J Med Chem* 48(21):6523–6543
41. Morphy R, Rankovic Z (2006) The physicochemical challenges of designing multiple ligands. *J Med Chem* 49(16):4961–4970
42. Wilson GL, Lill MA (2011) Integrating structure-based and ligand-based approaches for computational drug design. *Future Med Chem* 3(6):735–750
43. Wong YH, Lin CL, Chen TS, Chen CA, Jiang PS, Lai YH et al (2015) Multiple target drug cocktail design for attacking the core network markers of four cancers using ligand-based and structure-based virtual screening methods. *BMC Med Genom* 8(Suppl 4):S4
44. Cramer RD (2012) The inevitable QSAR renaissance. *J Comput Aid Mol Des* 26(1):35–38
45. Cherkasov A, Muratov EN, Fourches D, Varnek A, Baskin II, Cronin M et al (2014) QSAR modeling: where have you been? Where are you going to? *J Med Chem* 57(12):4977–5010
46. Hu BJ, Lill MA (2014) PharmDock: a pharmacophore-based docking program. *J Cheminform* 6(1):14
47. Danishuddin, Khan AU (2016) Descriptors and their selection methods in QSAR analysis: paradigm for drug design. *Drug Discov Today* 21(8):1291–1302
48. Hughes RE, Nikolic K, Ramsay RR (2016) One for all? Hitting multiple Alzheimer's disease targets with one drug. *Front Neurosci* 10:177
49. Nikolic K, Mavridis L, Djikic T, Vucicevic J, Agbaba D, Yelekcı K et al (2016) Drug design for CNS diseases: polypharmacological profiling of compounds using cheminformatic, 3D-QSAR and virtual screening methodologies. *Front Neurosci* 10:265
50. Mavridis L, Mitchell JB (2013) Predicting the protein targets for athletic performance-enhancing substances. *J Cheminform* 5(1):31
51. Nikolic K, Mavridis L, Bautista-Aguilera OM, Marco-Contelles J, Stark H, Carreiras MD et al (2015) Predicting targets of compounds against neurological diseases using cheminformatic methodology. *J Comput Aid Mol Des* 29(2):183–198
52. Ismaili L, Refouvelet B, Bencheikroun M, Brogi S, Brindisi M, Gemma S et al (2017) Multitarget compounds bearing tacrine- and donepezil-like structural and functional motifs for the potential treatment of Alzheimer's disease. *Prog Neurobiol* 151:4–34
53. Sliwoski G, Kothiwale S, Meiler J, Lowe EW Jr (2014) Computational methods in drug discovery. *Pharmacol Rev* 66(1):334–395
54. Vucicevic J, Srdic-Rajic T, Pieroni M, Laurila JM, Perovic V, Tassini S et al (2016) A combined ligand- and structure-based approach for the identification of rilmenidine-derived compounds which synergize the antitumor effects of doxorubicin. *Bioorg Med Chem* 24(14):3174–3183
55. Baurin N, Baker R, Richardson C, Chen I, Foloppe N, Potter A et al (2004) Drug-like annotation and duplicate analysis of a 23-supplier chemical database totalling 2.7 million compounds. *J Chem Inf Comput Sci* 44(2):643–651
56. Lepailler A, Freret T, Lemaître S, Boulouard M, Dauphin F, Hinschberger A et al (2014) Dual histamine H3R/serotonin 5-HT4R ligands with anti-amnesic properties: pharmacophore-based virtual screening and polypharmacology. *J Chem Inf Model* 54(6):1773–1784
57. Bottegoni G, Veronesi M, Bisignani P, Kacker P, Favia AD, Cavalli A (2016) Development and application of a virtual screening protocol for the identification of multitarget fragments. *ChemMedChem* 11(12):1259–1263
58. Bautista-Aguilera OM, Esteban G, Bolea I, Nikolic K, Agbaba D, Moraleda I et al (2014) Design, synthesis, pharmacological evaluation, QSAR analysis, molecular modeling and ADMET of novel donepezil-indolyl hybrids as multipotent cholinesterase/monoamine oxidase inhibitors for the potential treatment of Alzheimer's disease. *Eur J Med Chem* 75:82–95
59. Bautista-Aguilera OM, Samadi A, Chioua M, Nikolic K, Filipic S, Agbaba D et al (2014) *N*-Methyl-*N*-((1-methyl-5-(3-(1-(2-methylbenzyl) piperidin-4-yl)propoxy)-1H-indol-2-yl)methyl)prop-2-yn-1-amine, a new cholinesterase and monoamine oxidase dual inhibitor. *J Med Chem* 57(24):10455–10463
60. Bautista-Aguilera OM, Esteban G, Chioua M, Nikolic K, Agbaba D, Moraleda I et al (2014) Multipotent cholinesterase/monoamine oxidase inhibitors for the treatment of Alzheimer's disease: design, synthesis, biochemical evaluation, ADMET, molecular modeling, and QSAR analysis of novel donepezil-pyridyl hybrids. *Drug Des Dev Ther* 8:1893–1910
61. Butini S, Nikolic K, Kassel S, Bruckmann H, Filipic S, Agbaba D et al (2016) Polypharmacology of dopamine receptor ligands. *Prog Neurobiol* 142:68–103
62. Micheli F (2011) Recent advances in the development of dopamine D3 receptor antagonists: a medicinal chemistry perspective. *ChemMedChem* 6(7):1152–1162
63. Kiss B, Horvath A, Nemethy Z, Schmidt E, Laszlovszky I, Bugovics G et al (2010) Cariprazine (RGH-188), a dopamine D-3 receptor-preferring, D-3/D-2 dopamine receptor antagonist-partial agonist antipsychotic candidate. In vitro and neurochemical profile. *J Pharmacol Exp Ther* 333(1):328–340
64. Meng XY, Zhang HX, Mezei M, Cui M (2011) Molecular docking: a powerful approach for structure-based drug discovery. *Curr Comput Aided Drug Des* 7(2):146–157
65. Wu GS, Robertson DH, Brooks CL, Vieth M (2003) Detailed analysis of grid-based molecular docking: a case study of CDOCKER - A CHARMm-based MD docking algorithm. *J Comput Chem* 24(13):1549–1562
66. Jones G, Willett P, Glen RC (1995) Molecular recognition of receptor-sites using a genetic algorithm with a description of desolvation. *J Mol Biol* 245(1):43–53
67. Morris GM, Huey R, Lindstrom W, Sanner MF, Belew RK, Goodsell DS et al (2009) AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility. *J Comput Chem* 30(16):2785–2791
68. Bolea I, Juarez-Jimenez J, de Los Rios C, Chioua M, Pouplana R, Luque FJ et al (2011) Synthesis, biological evaluation, and molecular modeling of donepezil and *N*-[(5-(benzyloxy)-1-methyl-1H-indol-2-yl)methyl]-*N*-methylprop-2-yn-1-amine hybrids as new multipotent cholinesterase/monoamine oxidase inhibitors for the treatment of Alzheimer's disease. *J Med Chem* 54(24):8251–8270
69. Marco-Contelles J, Leon R, de los Rios C, Guglietta A, Terencio J, Lopez MG et al (2006) Novel multipotent tacrine-dihydropyridine hybrids with improved acetylcholinesterase inhibitory and neuroprotective activities as potential drugs for the treatment of Alzheimer's disease. *J Med Chem* 49(26):7607–7610

70. Marco-Contelles J, Leon R, de los Rios C, Samadi A, Bartolini M, Andrisano V et al (2009) Tacripyrines, the First tacrine-dihydropyridine hybrids, as multitarget-directed ligands for the treatment of Alzheimer's disease. *J Med Chem* 52(9):2724–2732
71. Leon R, Garcia AG, Marco-Contelles J (2013) Recent advances in the multitarget-directed ligands approach for the treatment of Alzheimer's disease. *Med Res Rev* 33(1):139–189
72. Pajouhesh H, Lenz GR (2005) Medicinal chemical properties of successful central nervous system drugs. *NeuroRx* 2(4):541–553
73. Rankovic Z (2015) Designing CNS drugs for optimal brain exposure. Blood–brain barrier in drug discovery. Wiley, Hoboken, pp 385–424
74. Rankovic Z (2015) CNS drug design: balancing physicochemical properties for optimal brain exposure. *J Med Chem* 58(6):2584–2608
75. Bingham M, Rankovic Z (2012) Chapter 18: medicinal chemistry challenges in CNS drug discovery. Drug discovery for psychiatric disorders. The Royal Society of Chemistry, Cambridge, pp 465–509
76. Hitchcock SA, Pennington LD (2006) Structure–brain exposure relationships. *J Med Chem* 49(26):7559–7583
77. Leeson PD, Springthorpe B (2007) The influence of drug-like concepts on decision-making in medicinal chemistry. *Nat Rev Drug Discov* 6(11):881–890
78. Leeson PD, Davis AM (2004) Time-related differences in the physical property profiles of oral drugs. *J Med Chem* 47(25):6338–6348
79. Weiss MM, Williamson T, Babu-Khan S, Bartberger MD, Brown J, Chen K et al (2012) Design and preparation of a potent series of hydroxyethylamine containing beta-secretase inhibitors that demonstrate robust reduction of central beta-amyloid. *J Med Chem* 55(21):9009–9024
80. Raub TJ, Lutzke BS, Andrus PK, Sawada GA, Staton BA (2006) Early pre-clinical evaluation of brain exposure in support of hit identification and lead optimization. In: Borchardt RT, Kerns EH, Hageman MJ, Thakker DR, Stevens JL (eds) Optimizing the "Drug-Like" properties of leads in drug discovery. Springer, New York, pp 355–410
81. Alelyunas YW, Empfield JR, McCarthy D, Spreen RC, Bui K, Pelosi-Kilby L et al (2010) Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate. *Bioorg Med Chem Lett* 20(24):7312–7316
82. Ghose AK, Herbertz T, Hudkins RL, Dorsey BD, Mallamo JP (2012) Knowledge-based, central nervous system (CNS) lead selection and lead optimization for CNS drug discovery. *ACS Chem Neurosci* 3(1):50–68
83. Hitchcock SA (2012) Structural modifications that alter the P-glycoprotein efflux properties of compounds. *J Med Chem* 55(11):4877–4895
84. Desai PV, Sawada GA, Watson IA, Raub TJ (2013) Integration of in silico and in vitro tools for scaffold optimization during drug discovery: predicting P-glycoprotein efflux. *Mol Pharm* 10(4):1249–1261
85. Kozikowski A, Roth B, Tropsha A (2006) Why academic drug discovery makes sense. *Science* 313(5791):1235–1236
86. Patridge E, Gareiss P, Kinch M, Hoyer D (2015) An analysis of original research contributions toward FDA-approved drugs. *Drug Discov Today* 20(10):1182–1187
87. Carlsson J, Coleman RG, Setola V, Irwin JJ, Fan H, Schlessinger A et al (2011) Ligand discovery from a dopamine D-3 receptor homology model and crystal structure. *Nat Chem Biol* 7(11):769–778
88. Warne T, Serrano-Vega M, Baker J, Moukhametdzanov R, Edwards P, Henderson R et al (2008) Structure of a β_1 -adrenergic G-protein-coupled receptor. *Nature* 454(7203):486–491
89. Munk C, Isberg V, Mordalski S, Harpsøe K, Rataj K, Hauser AS et al (2016) GPCRdb: the G protein-coupled receptor database—an introduction. *Biochem Pharmacol* 173(14):2195–2207
90. Bautista-Aguilera O, Hagenow Stefanie, Palomino-Antolin Alejandra, Farré-Alins Víctor, Ismaili Lhassane, Joffrin Pierre-Louis et al (2017) Multitarget-directed ligands combining cholinesterase and monoamine oxidase inhibition with H3R antagonism for neurodegenerative diseases. *Angew Chem* 56:12765–12769
91. Roth S, Kholodenko B, Smit M, Bruggeman F (2015) G protein-coupled receptor signalling networks from a systems perspective. *Mol Pharmacol* 88(3):604–616
92. Wacker D, Stevens R, Roth B (2017) How ligands illuminate GPCR molecular pharmacology. *Cell Tissue Res* 170(3):414–427
93. Jazayeri A, Andrews S, Marshall F (2017) Structurally enabled discovery of adenosine A2A receptor antagonists. *Chem Rev* 117(1):21–37
94. Kasai R, Suzuki K, Prossnitz E, Koyama-Honda I, Nakada C, Fujiwara T et al (2011) Full characterization of GPCR monomer-dimer dynamic equilibrium by single molecule imaging. *J Cell Biol* 192(3):463–480
95. Rodríguez-Ruiz M, Moreno E, Moreno-Delgado D, Navarro G, Mallol J, Cortés A et al (2017) Heteroreceptor complexes formed by dopamine D1, histamine H3, and N-methyl-D-aspartate glutamate receptors as targets to prevent neuronal death in Alzheimer's disease. *Mol Neurobiol* 54(6):4537–4550
96. Marshall F (2016) Visualizing GPCR 'Megaplexes' which enable sustained intracellular signaling. *Trends Biochem Sci* 41(12):985–986
97. Copeland RA (2005) Evaluation of enzyme inhibitors in drug discovery: a guide for medicinal chemists and pharmacologists. Wiley, Hoboken
98. Tipton KF (2002) Principles of enzyme assay and kinetic studies. In: Eysenthal R, Danson MJ (eds) Enzyme assays: a practical approach, vol 257. Oxford University Press, London, pp 1–47
99. McDonald AG, Tipton KF (2001) Enzymes: irreversible inhibition. eLS. Wiley. <https://doi.org/10.1002/9780470015902.a0000601.pub2>
100. Ramsay RR, Tipton KF (2017) Assessment of enzyme inhibition: a review with examples from the development of monoamine oxidase and cholinesterase inhibitory drugs. *Molecules* 22(7):1192
101. Bar-Am O, Amit T, Youdim MB, Weinreb O (2016) Neuroprotective and neurorestorative potential of propargylamine derivatives in ageing: focus on mitochondrial targets. *J Neural Transm* 123(2):125–135
102. Naoi M, Maruyama W (2010) Monoamine oxidase inhibitors as neuroprotective agents in age-dependent neurodegenerative disorders. *Curr Pharm Des* 16(25):2799–2817
103. Brand MB, Nicholls DG (2011) Assessing mitochondrial dysfunction in cells. *Biochem J* 435:297–312
104. Johnson M, Bobrovskaya L (2015) An update on the rotenone models of Parkinson's disease: their ability to reproduce the features of clinical disease and model gene–environment interactions. *Neurotoxicology* 46:101–116
105. Zhang L, Trushin S, Christensen TA, Bachmeier BV, Gateno B, Schroeder A et al (2017) Altered brain energetics induces mitochondrial fission arrest in Alzheimer's disease. *Sci Rep* 6:18725
106. Reddy P, Manczak M, Kandimalla R (2017) Mitochondria-targeted small molecule SS31: a potential candidate for the treatment of Alzheimer's disease. *Hum Mol Genet* 26(8):1483–1496
107. Sharpe M, Han J, Baskin A, Baskin D (2015) Design and synthesis of a MAO-B-selectively activated prodrug based on MPTP: a mitochondria-targeting chemotherapeutic agent for treatment of human malignant gliomas. *ChemMedChem* 10:621–628
108. Nadanaciva S, Aleo M, Strock C, Stedman D, Wang H, Will Y (2013) Toxicity assessments of nonsteroidal anti-inflammatory drugs in isolated mitochondria, rat hepatocytes, and zebrafish show good concordance across chemical classes. *Toxicol Appl Pharmacol* 272(2):263–271
109. De Deurwaerdere P, Binda C, Corne R, Leone C, Valeri A, Valoti M et al (2017) Comparative analysis of the neurochemical profile and MAO inhibition properties of N-(furan-2-ylmethyl)-N-methylprop-2-yn-1-amine. *ACS Chem Neurosci* 8(5):1026–1035
110. Geerts H, Spiros A, Roberts P (2015) Assessing the synergy between cholinomimetics and memantine as augmentation therapy in cognitive impairment in schizophrenia. A virtual human patient trial using quantitative systems pharmacology. *Front Pharmacol* 6:198
111. Golde TE (2016) Overcoming translational barriers impeding development of Alzheimer's disease modifying therapies. *J Neurochem* 139:224–236